retatrutide clinical trial results 2024 2025 press release Commercial Availability Timeline: Key Milestones and Costs ADA '26: Lilly's dominance, Pfizer's – retatrutide type 2 diabetes phase

However, patients frequently stop treatment once symptoms like itching improve, even if the underlying condition is still active

This drugs possible impacts on PXR and cardiovascular risk factors such as dyslipidemia are currently unknown

CrossRef Technical research advances in PET radionuclide tracers for diagnosing hepatocellular carcinoma Yi He, Chunyin Zhang Clinical and Translational Imaging .2026;[Epub] CrossRef Metabolic Reprogramming Nanoplatform for Broad-Spectrum Lactate Suppression to Reverse High Intensity Focused Ultrasound-Induced Immunosuppression in Hepatocellular Carcinoma Therapy Zeyan Huang, Yi Lin, Rui Tang, Qi Wang, Nianhong Wu, Li Wan, Pan Li, Ju Huang ACS Nano .2026

Glucagon-Like Peptide-1 Receptor Agonists (StatPearls Publishing, 2024)